PMID- 34012411
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210522
IS  - 1664-0640 (Print)
IS  - 1664-0640 (Electronic)
IS  - 1664-0640 (Linking)
VI  - 12
DP  - 2021
TI  - Assessment of the Minimum Clinically Important Difference in Symptoms and 
      Functions of Patients With Acute Schizophrenia: A Post hoc Analysis of an 
      Open-Label, Single-Arm Multicenter Study.
PG  - 653916
LID - 10.3389/fpsyt.2021.653916 [doi]
LID - 653916
AB  - The purpose of this study was to evaluate the application of the minimum 
      clinically important difference (MCID) concept to clinical results in Chinese 
      patients with acutely exacerbated schizophrenia. The original study was an 
      8-week, open-label, single-arm, multicenter study of flexible doses of 
      paliperidone-extended release (pali-ER) in Chinese patients with acutely 
      exacerbated schizophrenia. This is a post hoc analysis to determine the MCID 
      value of PANSS, PSP and evaluate the responsiveness of each outcome measurements 
      in the acute phase of schizophrenia. The responsiveness of the four measurements 
      (PANSS, PANSS reduction rate, PSP, CGI-S) was analyzed. Four hundred ninety nine 
      patients completed the 8-week follow-up and were finally used for this post hoc 
      analysis. The MCID calculated by different approaches varied from 14.02 to 31.50 
      for PANSS, 15.14 to 42.79% for PANSS reduction rate, and 7.62 to 13.13% for PSP. 
      In addition, the improvement of the CGI-S owned the highest responsiveness of the 
      four outcome measurements. The threshold value of MCID for schizophrenia patients 
      was determined by choice of the assessment method to an extent. In addition, the 
      CGI-S score appeared to be the most valid and responsive measure of effectiveness 
      for the acute phase of schizophrenia when take the treatment satisfaction of 
      patients as anchor.
CI  - Copyright (c) 2021 Si, Shi, Sun, Zhang and Zhang.
FAU - Si, Tianmei
AU  - Si T
AD  - Peking University Sixth Hospital (Institute of Mental Health), Beijing, China.
AD  - NHC Key Laboratory of Mental Health (Peking University) & National Clinical 
      Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing, 
      China.
FAU - Shi, Chuan
AU  - Shi C
AD  - Peking University Sixth Hospital (Institute of Mental Health), Beijing, China.
AD  - NHC Key Laboratory of Mental Health (Peking University) & National Clinical 
      Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing, 
      China.
FAU - Sun, Ling
AU  - Sun L
AD  - Tianjin Anding Hospital, Tianjin, China.
FAU - Zhang, Yilong
AU  - Zhang Y
AD  - Xian Janssen Pharmaceuticals, Beijing, China.
FAU - Zhang, Lili
AU  - Zhang L
AD  - Xian Janssen Pharmaceuticals, Beijing, China.
LA  - eng
PT  - Journal Article
DEP - 20210503
PL  - Switzerland
TA  - Front Psychiatry
JT  - Frontiers in psychiatry
JID - 101545006
PMC - PMC8126618
OTO - NOTNLM
OT  - clinical global impression-severity scale
OT  - minimum clinically important difference
OT  - personal and social performance
OT  - positive and negative syndrome scale
OT  - schizophrenia
COIS- YZ and LZ were employees of Xian Janssen Pharmaceuticals at the time during which 
      the work was undertaken. This work is a post-hoc analysis of a Xian Janssen 
      sponsored phase 3 study R0776477-SCH-3034. The remaining authors declare that the 
      research was conducted in the absence of any other commercial or financial 
      relationships that could be construed as a potential conflict of interest.
EDAT- 2021/05/21 06:00
MHDA- 2021/05/21 06:01
PMCR- 2021/05/03
CRDT- 2021/05/20 06:40
PHST- 2021/01/15 00:00 [received]
PHST- 2021/03/29 00:00 [accepted]
PHST- 2021/05/20 06:40 [entrez]
PHST- 2021/05/21 06:00 [pubmed]
PHST- 2021/05/21 06:01 [medline]
PHST- 2021/05/03 00:00 [pmc-release]
AID - 10.3389/fpsyt.2021.653916 [doi]
PST - epublish
SO  - Front Psychiatry. 2021 May 3;12:653916. doi: 10.3389/fpsyt.2021.653916. 
      eCollection 2021.